Palvella Therapeutics, Inc. (PVLA) Return on Sales (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Return on Sales for 11 consecutive years, with 2905.67% as the latest value for Q4 2024.
- On a quarterly basis, Return on Sales fell 290530.0% to 2905.67% in Q4 2024 year-over-year; TTM through Dec 2024 was 2905.67%, a 290655.0% decrease, with the full-year FY2024 number at 40.54%, up 3598.0% from a year prior.
- Return on Sales was 2905.67% for Q4 2024 at Palvella Therapeutics, down from 144.15% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 144.15% in Q3 2024 to a low of 2905.67% in Q4 2024.
- A 5-year average of 177.19% and a median of 2.08% in 2022 define the central range for Return on Sales.
- Biggest YoY gain for Return on Sales was 14700bps in 2024; the steepest drop was -290530bps in 2024.
- Palvella Therapeutics' Return on Sales stood at 8.17% in 2020, then soared by 88bps to 0.99% in 2021, then tumbled by -83bps to 1.82% in 2022, then skyrocketed by 80bps to 0.37% in 2023, then crashed by -785297bps to 2905.67% in 2024.
- Per Business Quant, the three most recent readings for PVLA's Return on Sales are 2905.67% (Q4 2024), 144.15% (Q3 2024), and 695.33% (Q2 2024).